VA Secures Record $10B in Pharmaceutical Savings

The Department of Veterans Affairs announced it secured more than $10 billion in pharmaceutical price reductions during fiscal year 2026,

X / Twitter
LinkedIn
Print

The Department of Veterans Affairs announced it secured more than $10 billion in pharmaceutical price reductions during fiscal year 2026, a record figure for the VA health system revealed Aug. 13 that expands its capacity to treat more veterans within existing budget constraints.

The savings represent accumulated discounts across the VA’s entire formulary, according to the department’s announcement. The VA purchases prescription drugs at negotiated prices significantly lower than the commercial market due to federal procurement authority.

The VA’s pharmaceutical purchasing power is rooted in a combination of statutory authorities. The Federal Supply Schedule, the 340B Drug Pricing Program, and direct negotiations with manufacturers allow the VA to obtain drugs at prices far below what Medicare, Medicaid, and private insurers typically pay.

For the roughly 9 million veterans enrolled in VA healthcare, the savings directly affect access to medications. Lower drug costs allow the VA to maintain broader formulary coverage and reduce or eliminate copayments that veterans would otherwise face.

The $10 billion figure is particularly significant as the VA health system faces growing demand from newly eligible veterans. The PACT Act, signed into law in 2022, expanded VA healthcare eligibility to millions of veterans exposed to toxic substances during military service, including burn pits in Iraq and Afghanistan. The resulting enrollment surge has strained VA resources.

The record savings also carry implications for the broader drug pricing debate. The VA’s ability to negotiate aggressively with pharmaceutical companies is frequently cited by advocates of expanding government negotiating authority to other federal health programs.

Pharmaceutical industry groups have argued that the VA’s pricing model is not directly comparable to the commercial market because the VA operates as an integrated healthcare system with a closed formulary that can exclude drugs that do not offer competitive pricing.

Veterans service organizations praised the savings as evidence of the VA’s effective stewardship of taxpayer resources.

Sources

Filed Under

Share This Story

X / Twitter
LinkedIn
Email
Print

Advertisement

300 × 250

Related

CMS Invests $120M in Indiana Maternal and Infant Health

CMS Blocks $1.6B in Fraudulent Medicare Lab Payments

Daily Dispatch

The morning briefing on federal government — delivered to your inbox before 7 AM.

Advertisement

300 × 120

More from Defense

BLS Releases Metro Area Employment Data for Hundreds of US Cities

The Bureau of Labor Statistics released its monthly Metropolitan Area Employment and Unemployment report on Sept. 2, providing localized labor market data for hundreds of U.S. cities and metropolitan statistical...

Federal Student Aid Says FAFSA Will Meet Oct. 1 Deadline

Federal Student Aid announced the 2027-28 Free Application for Federal Student Aid will be available to students by Oct. 1, the congressionally mandated opening date, according to a release on...

Reclamation Opens Negotiations for California’s Sites Reservoir Project

The Bureau of Reclamation announced public negotiations with the Sites Project Authority for a water storage contract tied to the proposed Sites Reservoir Project in California on Sept. 2, advancing...